Fosun Pharma, ClavisBio Sign Five-Year Drug Collaboration Agreement; Shanghai Shares Rise 3%

MT Newswires Live11:57

Shanghai Fosun Pharmaceutical (SHA:600196, HKG:2196) subsidiary Fosun Pharma Industry and ClavisBio signed a five-year drug collaboration agreement, according to a Friday filing with the Shanghai bourse.

The two companies will promote the preclinical development of the drugs.

ClavisBio will have the option to exclusively license the development, production, and commercialization of the products worldwide except in mainland China, Hong Kong, and Macau, where Fosun will have rights.

Should ClavisBio exercise its right to the projects, Fosun will be eligible for up to $362.5 million for a single project.

Fosun will also be entitled to royalties and a predetermined minority stake in a new project company set up by ClavisBio controlling shareholder AditumBioFund3 for the project, the filing said.

Shares in Fosun Pharma rose 3% in Shanghai and 2% in Hong Kong during late morning trading on Friday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment